Free Trial
NASDAQ:IFRX

InflaRx (IFRX) Stock Price, News & Analysis

InflaRx logo
$0.88 -0.01 (-0.58%)
As of 09:34 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About InflaRx Stock (NASDAQ:IFRX)

Key Stats

Today's Range
$0.86
$0.86
50-Day Range
$0.73
$1.85
52-Week Range
$0.71
$2.82
Volume
9,387 shs
Average Volume
305,804 shs
Market Capitalization
$58.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.60
Consensus Rating
Buy

Company Overview

InflaRx Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
55th Percentile Overall Score

IFRX MarketRank™: 

InflaRx scored higher than 55% of companies evaluated by MarketBeat, and ranked 497th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    InflaRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    InflaRx has only been the subject of 3 research reports in the past 90 days.

  • Read more about InflaRx's stock forecast and price target.
  • Earnings Growth

    Earnings for InflaRx are expected to decrease in the coming year, from ($1.04) to ($1.16) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of InflaRx is -1.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of InflaRx is -1.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    InflaRx has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about InflaRx's valuation and earnings.
  • Percentage of Shares Shorted

    2.21% of the float of InflaRx has been sold short.
  • Short Interest Ratio / Days to Cover

    InflaRx has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in InflaRx has recently increased by 5.08%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    InflaRx does not currently pay a dividend.

  • Dividend Growth

    InflaRx does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.21% of the float of InflaRx has been sold short.
  • Short Interest Ratio / Days to Cover

    InflaRx has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in InflaRx has recently increased by 5.08%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    InflaRx has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.01 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for InflaRx this week, compared to 2 articles on an average week.
  • Search Interest

    2 people have searched for IFRX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, InflaRx insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    16.30% of the stock of InflaRx is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    42.39% of the stock of InflaRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about InflaRx's insider trading history.
Receive IFRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InflaRx and its competitors with MarketBeat's FREE daily newsletter.

IFRX Stock News Headlines

A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Headlines

IFRX Stock Analysis - Frequently Asked Questions

InflaRx's stock was trading at $2.47 at the start of the year. Since then, IFRX stock has decreased by 64.4% and is now trading at $0.8801.

InflaRx N.V. (NASDAQ:IFRX) issued its quarterly earnings results on Wednesday, May, 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $0.04. The business earned $0.03 million during the quarter, compared to analyst estimates of $0.03 million.

InflaRx (IFRX) raised $100 million in an initial public offering on Wednesday, November 8th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

Shares of IFRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that InflaRx investors own include G1 Therapeutics (GTHX), Xeris Biopharma (XERS), Bristol Myers Squibb (BMY), Enterprise Products Partners (EPD), Exelixis (EXEL), Tesla (TSLA) and Alibaba Group (BABA).

Company Calendar

Last Earnings
5/07/2025
Today
7/14/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IFRX
CIK
1708688
Employees
60
Year Founded
N/A

Price Target and Rating

High Price Target
$10.00
Low Price Target
$2.00
Potential Upside/Downside
+654.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.82)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$49.85 million
Net Margins
N/A
Pretax Margin
-33,646.85%
Return on Equity
-64.17%
Return on Assets
-53.39%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.28
Quick Ratio
4.86

Sales & Book Value

Annual Sales
$180 thousand
Price / Sales
326.33
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.13 per share
Price / Book
0.77

Miscellaneous

Outstanding Shares
67,130,000
Free Float
56,190,000
Market Cap
$58.74 million
Optionable
Optionable
Beta
1.29
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:IFRX) was last updated on 7/14/2025 by MarketBeat.com Staff
From Our Partners